EU Press Dialogue

Dialogue topic on March 7, 2012

"Can society afford innovative cancer treatment?"

Time:

March 7, 2012; 11:00 am to 1:00 pm, followed by a lunch buffet

Place:

Hotel Radisson Blu Royal,
Rue du Fosse-aux-Loups 47
1000 Brussels
Belgium

Schedule:

• Greeting
• Keynote address Science: Eric van Cutsem, ESMO
• Keynote address Patient Advocacy Group: Jola Gore-Booth, Europacolon
• Keynote address HTA: Bengt Jönsson, Stockholm School of Economics
• Keynote address Industry: Philip Ashman, Bayer HealthCare
• Moderated discussion (Gary Finnegan)
• Lunch buffet
• Marketplace session

Panel discussion:

Despite significant advances in the fight against cancer, a great medical need remains for therapies that can prolong life or improve the quality of life for cancer patients.
WHO estimates 12 million cancer deaths worldwide in 2030 compared to 7.6 million in 2008.
As health care expenditures worldwide are rapidly increasing due to the ageing population, a societal debate is emerging over the value of cancer treatments and the necessary research investment.
What is a prolonged life or an improved quality of life worth to patients and society?

Speakers

Prof. Dr. Eric van Cutsem, ESMO	Jola Gore-Booth, Europacolon	Prof. Dr. Bengt Jönsson, Stockholm School of Economics	Dr. Philip Ashman, Bayer HealthCare	Gary Finnegan, Moderator

Download images

• Prof. Dr. Eric van Cutsem, ESMO, JPG (4.8MB)
• Jola Gore-Booth, Europacolon, JPG (4.1MB)
• Prof. Dr. Bengt Jönsson, Stockholm School of Economics, JPG (4.7MB)
• Dr. Philip Ashman, Bayer HealthCare, JPG (4.5MB)
• Gary Finnegan, Moderator, JPG (4.1MB)

Download abstracts

• Jola Gore-Booth, Europacolon, PDF (60KB)
• Prof. Dr. Bengt Jönsson, Stockholm School of Economics, PDF (67KB)
• Dr. Philip Ashman, Bayer HealthCare, PDF (8KB)

Event archive Dialogue Lunch

• Is society prepared for the diseases of an ageing population? October 21, 2011
  (event language: German)
• Assessment on medicines. September 14, 2010 (event language: German)